Ritter Pharmaceuticals Inc (RTTR)

[powerbattles]

On March 3, 2020, Ritter Pharmaceuticals, Inc. (the “Company”) filed a supplement no. 1 to the prospectus supplement, dated November 7, 2019 with the Securities and Exchange Commission (the “Supplement to Prospectus Supplement”) in connection with the offering of up to an aggregate of $8,030,917 shares of the Company’s common stock, $0.001 par value per share, pursuant to the Sales Agreement, dated as of November 6, 2019, with A.G.P./Alliance Global Partners, as agent, under its existing Registration Statement on Form S-3 (File No 333-232798), which became effective on August 1, 2019 (the “Registration Statement”). The purpose of the Supplement to Prospectus Supplement was to increase the aggregate offering price of shares of common stock that may be sold under the Sales Agreement from $3,673,159 to $8,030,917. The Company has already sold $3,658,718 of this amount under the Sales Agreement.